Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Imago BioSciences, Inc. | d150500dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 26, 2021
IMAGO BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-40604 | 45-4915810 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
329 Oyster Point Blvd., 3rd Floor
South San Francisco, California 94080
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (415) 529-5055
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| Common Stock | IMGO | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events. |
As previously disclosed, on July 20, 2021, Imago BioSciences, Inc. (the “Company”) completed its initial public offering of 8,400,000 shares of its common stock at a price to the public of $16.00 per share. In connection with the Underwriting Agreement, dated July 15, 2021, by and among the Company and the underwriters of the initial public offering, the underwriters have fully exercised their option to purchase an additional 1,260,000 shares of common stock. A copy of the press release announcing the exercise of the underwriters’ option is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
Reference is made to the Exhibit Index attached hereto.
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Press release dated July 26, 2021. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IMAGO BIOSCIENCES, INC. | ||||||
| Date: July 26, 2021 | By: | /s/ Hugh Y. Rienhoff, Jr., M.D. | ||||
| Hugh Y. Rienhoff, Jr., M.D. | ||||||
| Chief Executive Officer | ||||||